Slides
Page 1
1 Third Quarter 2026 Financial Results November 3, 2026
Page 2
2 IMPORTANT NOTICE Forward-Looking Statements & Non-GAAP Measures In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements include total sales growth, EPS and Adjusted EBITDA guidance and statements about our business expectations, and are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make”, or other comparable terms. A fuller discussion of our operations, financial condition and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we file with the United States Securities and Exchange Commission, or SEC, including our Annual Report on Form 10-K, and will be contained in subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations. Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: our dependence on third parties for the manufacture and supply of our products and where we manufacture products, our dependence on third parties for raw materials or purchased components; risks relating to the achievement of our strategic growth objectives, including anticipated results of restructuring and value creation initiatives; risks related to the Strategic Partnership Agreement with KKR Hawaii Aggregator L.P. entered into in January 2025; transitions in senior company leadership (including, without limitation, our Chief Executive Officer, Chief Financial Officer, and other executive officers); our ability to develop or acquire and maintain and protect new products (particularly technology and specialty products) and services and utilize new technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions and joint ventures, including the failure to achieve anticipated synergies/benefits, as well as significant demands on our operations, information systems, legal, regulatory, compliance, financial and human resources functions in connection with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or other purchasing incentives; risks related to the sale of corporate brand products; risks related to activist investors; security risks associated with our information systems and technology products and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident); effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; political, economic, and regulatory influences on the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers, and increases in fuel and energy costs; changes in laws and policies governing manufacturing, development and investment in territories and countries where we do business; general global and domestic macro-economic and political conditions, including inflation, deflation, recession, unemployment (and corresponding increase in under-insured populations), consumer confidence, sovereign debt levels, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies and changes to other economic indicators; failure to comply with existing and future regulatory requirements, including relating to health care; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or transmissions; changes in tax legislation, changes in tax rates and availability of certain tax deductions; risks related to product liability, intellectual property and other claims; risks associated with customs policies or legislative import restrictions; risks associated with disease outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or similar wide-spread public health concerns and other natural or man-made disasters; risks associated with our global operations; the threat or outbreak of war (including, without limitation, geopolitical wars), terrorism or public unrest (including, without limitation, the wars in Ukraine and Iran, the Israel-Gaza conflict and other unrest and threats in the Middle East and the possibility of a wider European or global conflict); changes to laws and policies governing foreign trade, tariffs and sanctions or greater restrictions on imports and exports, including changes to international trade agreements and the current imposition of (and the potential for additional) tariffs by the U.S. on numerous countries and retaliatory tariffs; supply chain disruption; litigation risks; new or unanticipated litigation developments and the status of litigation matters; our dependence on our senior management, employee hiring and retention, increases in labor costs or health care costs, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority. We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except as required by law. Included within this presentation are non-GAAP financial measures that supplement the Company’s Consolidated Statements of Income prepared under generally accepted accounting principles (GAAP). These non-GAAP financial measures adjust the Company’s actual results prepared under GAAP to exclude certain items. In the schedule attached to this presentation, the non-GAAP measures have been reconciled to and should be considered together with the Consolidated Statements of Income. Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. The impact of certain items that are excluded include integration and restructuring costs, amortization of acquisition-related assets, the insurance claim recovery associated with the cybersecurity incident, changes in contingent consideration, costs associated with shareholder advisory matters and select value creation consulting costs, and litigation settlements because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate and occur on an unpredictable basis. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures.
Page 3
3 Growth Outperforming Markets • +4.0% Worldwide sales led by +8.6% U.S. dental merchandise sales • +6.1% Specialty sales driven by growth in value & premium implants • +5.2% Technology sales driven by net new customers and price Unlocking Earnings Power • +13.0% non-GAAP EPS and +19.1% adjusted non-GAAP EPS* • ~30 bps gross margin expansion** driving underlying earnings growth • Stronger Q3 performance than expected thanks to outstanding execution, reinforces our confidence in delivering FY double-digit EPS growth Raising FY Guidance • Increasing FY2026 non-GAAP EPS to $5.53 at midpoint and Adj. EBITDA • Reflecting improved underlying performance and the impact of net tariff refund benefits • Investments in growth initiatives in Q4 to continue to drive share gains THIRD QUARTER 2026 Key Takeaways +4.0% Worldwide Sales • Volume from share gains • Strategic price realization • Continued company-owned brands growth Adj. EBITDA*** $321M vs. PY +8.7% Non-GAAP Diluted EPS**** $1.56 vs. PY +13.0% Revised FY Guidance: Total Sales +4.5% - 5.5% Adj. EBITDA High Single-Digits Non-GAAP EPS $5.50 - $5.56 vs. PY (at the midpoint) +11.3% *Refer to slide 21 for Impact of Net Tariff Refunds and Remeasurement Gains on Earnings Per Share. **Excludes the impact of net tariff refund benefits. ***Refer to slide 15 for a reconciliation of Non -GAAP Adj. EBITDA. ****Refer to slide 20 for our GAAP to Non -GAAP Reconciliation.
Page 4
4 STRATEGIC PRIORITIES Progress Advancing Our Strategic Priorities Accelerate Growth • Targeted investments to win new customers, and increase share of wallet • New product development in company-owned innovative exclusive products • Practice management software, Cloud-based/AI-enabled solutions; Medical Home Solutions Simplify the Business • De-layering the organization and expanding shared services • Centralized indirect procurement and pricing capabilities • Faster Decision Making Execution, Rigor & Discipline • Prioritizing investments and resources for growth • Productivity gains and strategic pricing • Disciplined capital and resource allocation Driving sustainable growth, unlocking increased earnings power
Page 5
5 Global Segments Sales ($M) LCI Growth* Commentary Global Medical $1,138 1.0% • 3.6% growth in our core medical business and 11.4% sales growth in Home Solutions, offset by lower point-of-care diagnostics and vaccines Specialty Products $391 3.4 % • In Europe we achieved good sales growth for both value and premium implants Eliminations $(45) • Growth led by our cloud -based platforms and new AI-enabled solutions Total $3,471 3.1% Sales Performance Technology $181 6.5 % • Inter-company product sales to Distribution *LCI growth defined as internal sales growth in local currencies. Distribution $2,944 2.9% • Winning new customers, expanding share of wallet, growing our company-owned and exclusive products Global Dental $1,806 • 5.1% merchandise sales growth driven primarily by volume from market share gains in the U.S. • 2.4% equipment sales growth driven by traditional equipment 4.1% THIRD QUARTER 2026
Page 6
6 $0.12 $0.06 $0.02 $0.19 ($0.23) $0.02 Q3 2025 EPS Operational Performance Share Repurchase** Interest, Net Tax Rate*** Tariff Refund Remeasurement Gain (Q3 2025) Q3 2026 EPS Non-GAAP Q3 EPS Bridge • +19.1% underlying adjusted EPS vs. PY excluding tariff refund benefits in Q3 2026 and remeasurement gain in Q3 2025 • Strong operational performance increases our confidence in the momentum we are building • +8.6% U.S. dental merchandise sales, reflecting increased volume from market share gains • Executed $125M Share Repurchases in the quarter *Refer to slide 21 for Impact of Net Tariff Refunds and Remeasurement Gains on Earnings Per Share. **Net of interest impact ***Tax rate favorability reflects treatment of the remeasurement gain in the prior year +13.0% vs. PY +19.1% Underlying adjusted EPS* vs. PY THIRD QUARTER 2026 $1.56 $1.38
Page 7
7 Sales: Total sales +3.7% with LCI sales +2.9% U.S. Dental merchandise sales +8.6% driven primarily by volume from market share gains Operating Income: 24.7% YoY operating income growth, excluding net tariff benefits operating income grew 13.6% YoY and margin expanded 60 bps Solid growth and company-owned brands share gains drove margin expansion $178 $221 Operating Income & Margin 3Q25 3Q26 Global Distribution & Value-Added Services Group $2,840 $2,944 Sales ($M) 3Q25 3Q26 7.5% 6.2% THIRD QUARTER 2026
Page 8
8 Sales: Total sales +6.1% with LCI sales +3.4% Driven by value and premium implants in Europe, as well as our SIN 360 value implant in the U.S. Operating Income: 13.5% YoY operating income growth and 81 bps margin expansion when excluding one-time impacts of tariff refunds and remeasurement gain recognized in the prior year Global Specialty Products Group $369 $391 Sales ($M) 3Q25 3Q26 $71 $56 Operating Income & Margin 3Q25 3Q26 14.3%19.3% Value and premium implants drive growth THIRD QUARTER 2026
Page 9
9 Sales: Total sales +5.2% with LCI sales +6.5% Growth led by our cloud-based platforms and new AI-enabled solutions Operating Income: 15.5% operating income growth year-over- year with operating margin expansion 260 bps driven by gross margin expansion primarily in our U.S. practice management business Global Technology Group $173 $181 Sales ($M) 3Q25 3Q26 $46 $53 Operating Income & Margin 3Q25 3Q26 26.5% 29.1% New product development and innovation drive growth THIRD QUARTER 2026
Page 10
10 $0M Invested Q3 $125M Share repurchases Q3 Return of Capital to Shareholders Acquisitions Capital Expenditures 2.8x Debt-to-Adj. EBITDA ratio as of September 26, 2026* Maintain investment grade balance sheet $330M Remaining share repurchase authorization at the end of Q3 Operating cash flow remains on track to exceed net income for the full year, reflecting the underlying quality of Henry Schein's earnings and disciplined working capital management. $161M Q3 2026 Operating Cashflow 1 *Refer to slide 15 for a reconciliation of Non-GAAP Adj. EBITDA. Debt reflects long-term debt, bank credit lines and letters of credit. CASH FLOW OUTLOOK Balanced Capital Allocation Strategy THIRD QUARTER 2026 $30M Invested Q3
Page 11
11 OUTLOOK Raising Full Year 2026 Guidance Prior Guidance New Guidance Total Sales Growth +4.5% – 5.5% +4.5% – 5.5% Non-GAAP Diluted EPS $5.29 – $5.39 $5.50 – $5.56 Adjusted EBITDA (Non-GAAP) Mid-High Single-Digits High Single-Digits • 11% growth of FY Non-GAAP diluted EPS guidance at the midpoint • Guidance assumes no significant additional tariff refunds or remeasurement gains for the remainder of 2026 • Effective non-GAAP tax rate of approximately 24% • Selective increase in investment to further drive growth initiatives already demonstrating strong results. These targeted investments will build on share gains delivered so far and strengthen Henry Schein’s growth trajectory into 2027 The Company is providing guidance for 2026 diluted EPS and for 2026 Adjusted EBITDA on a non-GAAP basis, as noted above. The Company is not providing a reconciliation of its 2026 non-GAAP diluted EPS guidance to its projected 2026 diluted EPS prepared on a GAAP basis, or its 2026 Adjusted EBITDA guidance to net income prepared on a GAAP basis. This is because the Company is unable to provide without unreasonable effort an estimate of restructuring expenses and related or similar costs, including its ongoing value-creation initiatives, and the corresponding tax effect, which will be included in the Company’s 2026 diluted EPS and net income, prepared on a GAAP basis. The inability to provide this reconciliation is due to the uncertainty and inherent difficulty of predicting the occurrence, magnitude, financial impact and timing of related costs. Management does not believe these items are representative of the Company’s underlying business performance. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results. *FY2026 Guidance is as of November 3, 2026 and should not be considered an update of guidance beyond that date. Guidance is for current continuing operations and does not include the impact of restructuring expenses and related costs, amortization expense of acquired intangible assets, the impairment of intangible assets, changes in contingent consideration, select implementation-related costs supporting value creation initiatives, and litigation settlements.
Page 12
12 Strong growth and strengthening financials Increased confidence in achieving value-creation goals Positioned to deliver double-digit earnings growth Momentum Building Toward Double-Digit Earnings Growth THIRD QUARTER 2026
Page 13
13 13 Appendix
Page 14
14 Q3 2026 Worldwide Financial Results* (in millions of USD except EPS) Q3 2026 (Non-GAAP) Q3 2025 (Non-GAAP) y/y ∆ Total sales $3,471 $3,339 4.0% Gross profit 1,105 1,026 7.7% Gross margin 31.83% 30.72% 111 bps Operating expenses (Non-GAAP)** 826 764 -8.1% Operating income (Non-GAAP)* $279 $262 6.6% Operating margin (Non-GAAP)** 8.03% 7.83% 20 bps Net income attributable to Henry Schein, Inc. (Non-GAAP)** $175 $167 4.7% Earnings per share (Non-GAAP)* $1.56 $1.38 13.0% Effective tax rate (Non-GAAP)** 23.7% 22.9% *Refer to slide 20 for our GAAP to Non-GAAP Reconciliation. **GAAP Results as follows: Q3 2026: Operating expenses $912, Operating income $193, Operating margin 5.57%, Net income $119, Earnings per share $1.06, Effective tax rate 23.1% Q3 2025: Operating expenses $862, Operating income $164, Operating margin 4.88%, Net income $101, Earnings per share $0.84, Effective tax rate 21.3%
Page 15
15 Adjusted EBITDA (in millions of USD) Q3 2026 Q3 2025 Net Income attributable to Henry Schein, Inc. (GAAP) $119 $101 Net Income attributable to noncontrolling interests 7 8 Net Income (GAAP) 126 109 Interest income (9) (9) Interest expense 42 38 Income taxes 37 28 Depreciation and amortization 86 80 Restructuring and related costs 22 34 Change in contingent consideration 1 6 Costs associated with shareholder advisory matters and select implementation related value creation consulting costs 18 10 Litigation settlements 1 2 Equity in earnings of affiliates, net of tax (3) (3) Adjusted EBITDA (Non-GAAP) $321 $295 We define Adjusted EBITDA as net income, excluding (i) net income attributable to noncontrolling interests, (ii) interest income and expense, (iii) income taxes, (iv) depreciation and amortization, (v) restructuring and related costs, (vi) change in contingent consideration, (vii) costs associated with shareholder advisory matters and select implementation related value creation consulting costs, (viii) litigation settlements, and (ix) equity in earnings of affiliates, net of tax. Amounts may not sum due to rounding.
Page 16
16 Q3 2026 Sales Summary Global Distribution & Value-Added Services Group (in millions of USD) Q3 2026 Q3 2025 y/y ∆ LCI* y/y ∆ Dental Merchandise $660 $607 8.6% 7.0% Dental Equipment 220 217 1.6% 1.6% Value-Added Services 53 57 -7.6% -7.6% Total Dental 933 881 5.9% 4.7% Medical 1,110 1,099 1.0% 1.0% Total U.S. Distribution & Value-Added Services $2,043 $1,980 3.2% 2.6% Dental Merchandise 635 603 5.4% 3.3% Dental Equipment 229 223 2.9% 3.2% Value-Added Services 9 7 16.4% 15.7% Total Dental 873 833 4.9% 3.4% Medical 28 27 4.2% 2.0% Total International Distribution & Value-Added Services $901 $860 4.8% 3.3% Global Dental 1,806 1,714 5.4% 4.1% Global Medical 1,138 1,126 1.1% 1.0% Total Global Distribution & Value-Added Services Group $2,944 $2,840 3.7% 2.9% *LCI growth defined as internal sales growth in local currencies.
Page 17
17 Q3 2026 Sales Summary Global Specialty Products Group* (in millions of USD) Q3 2026 Q3 2025 y/y ∆ LCI** y/y ∆ Global Specialty Products Group $391 $369 6.1% 3.4% *Global Specialty Products Group includes certain expenses related to managing company -owned products that support sales in the distribution businesses. **LCI growth defined as internal sales growth in local currencies.
Page 18
18 Q3 2026 Sales Summary Global Technology Group (in millions of USD) Q3 2026 Q3 2025 y/y ∆ LCI* y/y ∆ U.S. HS One $137 $130 5.1% 5.1% International HS One 38 36 6.3% 13.0% Global HS One 175 166 5.5% 6.9% Other 6 7 -3.2% -3.2% Global Technology Group $181 $173 5.2% 6.5% *LCI growth defined as internal sales growth in local currencies.
Page 19
19 Q3 2026 GAAP to Non-GAAP Income Statements (in millions of USD except EPS) Q3 2026 (GAAP) Restructuring and Related Costs Acquisition Intangible Amortization Change in Contingent Consideration Costs Associated with Shareholder Advisory Matters and Select Implementation Related Value Creation Consulting Costs Litigation Settlements Q3 2026 (Non-GAAP) Total sales $3,471 - - - - - $3,471 Gross profit 1,105 - - - - - 1,105 Selling, general and administrative 819 - - (1) (18) (1) 799 Depreciation and amortization 71 - (44) - - - 27 Restructuring and related costs 22 (22) - - - - - Operating income $193 $22 $44 $1 $18 $1 $279 Net interest expense and other (33) - - - - - (33) Income before taxes 160 22 44 1 18 1 246 Income taxes (37) (5) (11) (1) (4) (1) (59) Equity in earnings of affiliates 3 - - - - - 3 Net income 126 17 33 - 14 - 190 Less: Net income attributable to noncontrolling interests (7) (1) (7) - - - (15) Net income attributable to Henry Schein, Inc. 119 16 26 - 14 - 175 Earnings per share (Diluted) $1.06 $0.14 $0.23 - $0.12 - $1.56 Amounts may not sum due to rounding.
Page 20
20 GAAP to Non-GAAP Reconciliation Q3 2026 Financial Highlights This presentation includes both GAAP and non-GAAP financial results. Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures. Growth rates are based on actual values and may not recalculate due to rounding. Amounts may not sum due to rounding. Henry Schein, Inc. Third Quarter 2026 Analyst Presentation Q3 2026 - Financial Highlights (in millions, except per share data) Q3 2025 Q3 2026 Growth Q3 2025 Q3 2026 Q3 2025 Q3 2026 Q3 2025 Q3 2026 Q3 2025 Q3 2026 Q3 2025 Q3 2026 Q3 2025 Q3 2026 Growth Net Sales 3,339$ 3,471$ 4.0% 3,339$ 3,471$ 4.0% Operating Income 164 193 18.6% 34$ 22$ 46$ 44$ 6$ 1$ 2$ 1$ 10$ 18$ 262 279 6.6% Operating Margin 4.88% 5.57% 69 bps 7.83% 8.03% 20 bps Net Income 101 119 17.1% 25$ 16$ 27$ 26$ 5$ -$ 1$ -$ 7$ 14$ 167 175 4.7% Diluted EPS 0.84$ 1.06$ 26.2% 0.20$ 0.14$ 0.23$ 0.23$ 0.04$ -$ 0.01$ -$ 0.06$ 0.12$ 1.38$ 1.56$ 13.0% Reconciling Items GAAP Non-GAAP Costs Associated with Shareholder Advisory Matters and Select Value Creation Restructuring and Related Costs Acquisition Intangible Amortization Litigation Settlements Change in Contingent Consideration
Page 21
21 Impact of Net Tariff Refunds and Remeasurement Gains on Earnings Per Share Q3 2026 Financial Highlights Henry Schein, Inc. Third Quarter 2026 Analyst Presentation Q3 2026 - Impact of Net Tariff Refunds and Remeasurement Gains on Earnings Per Share 2026 2025 Growth GAAP diluted EPS attributable to Henry Schein, Inc. $ 1.06 $ 0.84 26.2% Non-GAAP adjustments (1) 0.50 0.54 Non-GAAP diluted EPS attributable to Henry Schein, Inc. 1.56 1.38 13.0% Net tariff refunds benefit, net of tax (2) (0.19) - Remeasurement gains, net of tax (3) 0.00 (0.23) Adjusted non-GAAP diluted EPS attributable to Henry Schein, Inc. $ 1.37 $ 1.15 19.1% Third Quarter Management presents adjusted non-GAAP diluted EPS excluding net tariff refund benefits and remeasurement gains as we believe this presentation facilitates comparison of the Company's underlying operating performance between periods. (1) See Exhibit B for adjustments reconciling GAAP diluted EPS attributable to Henry Schein, Inc. to non-GAAP diluted EPS attributable to Henry Schein, Inc. (2) Represents the net benefit, net of tax, from the International Emergency Economic Powers Act (IEEPA) tariff refunds recognized during the period. (3) Represents the benefits, net of tax, related to remeasurement to the fair value of previously held equity investments.
Page 22
22 GAAP to Non-GAAP Reconciliation 2025 Financial Highlights This presentation includes both GAAP and non-GAAP financial results. Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures. Growth rates are based on actual values and may not recalculate due to rounding. Amounts may not sum due to rounding. Henry Schein, Inc. Third Quarter 2026 Analyst Presentation Full Year 2025 Financial Highlights (in millions, except per share data) 2024 2025 Growth 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 2024 2025 Growth Net Sales 12,673$ 13,184$ 4.0% 12,673$ 13,184$ 4.0% Operating Income 621$ 653$ 5.2% 110$ 105$ 184$ 179$ (31)$ (20)$ 45$ (2)$ 5$ 5$ 12$ -$ 1$ 16$ 2$ 36$ 949$ 972$ 2.4% Operating Margin 4.90% 4.96% 6 bps 7.49% 7.37% (12) bps Net Income 390$ 398$ 2.2% 79$ 72$ 112$ 109 (23)$ (15)$ 35$ (2)$ 4$ 4$ 6$ -$ -$ 12$ 2$ 27$ 605$ 605$ -0.1% Diluted EPS 3.05$ 3.27$ 7.2% 0.62$ 0.59$ 0.88$ 0.90$ (0.18)$ (0.12)$ 0.27$ (0.02)$ 0.03$ 0.03$ 0.05$ -$ -$ 0.10$ 0.01$ 0.22$ 4.74$ 4.97$ 4.9% GAAP Cyber Incident- Insurance Proceeds, Net of Third-Party Advisory Costs Associated with Shareholder Advisory Matters Litigation Settlements Impairment of Intangible Assets Change in Contingent Consideration Non-GAAP Restructuring and Related Costs Acquisition Intangible Amortization Impairment of Capitalized Assets Reconciling Items